Entecavir (Cavir) vs tenofovir alafenamide (Vemlidy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Hepatitis B
Shared mechanism: HBV polymerase (reverse transcriptase) · full Chronic Hepatitis B pipeline
Entecavir (Cavir)
Developed by Hanmi Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
tenofovir alafenamide (Vemlidy)
Marketed by Gilead Sciences
NCT01940341 · Phase 3 · completed
This was an adequately powered, randomized, double-blind, active-controlled trial of 425 participants. The primary endpoint—HBV DNA suppression below 29 IU/mL at Week 48—met the prespecified non-inferiority margin for TAF compared with TDF, supporting strong evidence for a comparable antiviral effect.
Next expected readout: December 2026 · NCT06221657 (registry estimate)
Reported efficacy
Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL (Week 48): Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL (Week 48): TAF 25 mg 94 Percentage of participants | TDF 300 mg 92.9 Percentage of participants (met)
Result source: NCT01940341
Results for Chronic Hepatitis B
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Entecavir (Cavir): no structured comparison results are available for Chronic Hepatitis B.
tenofovir alafenamide (Vemlidy): registry results are on file for Chronic Hepatitis B, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Entecavir (Cavir)'s landscape · tenofovir alafenamide (Vemlidy)'s landscape